The 81st Annual Meeting of the Japanese Society of Hematology

Session information

Oral Session

Oral Session 1-10C AML: FLT3 Inhibitors

Fri. Oct 11, 2019 3:20 PM - 4:10 PM No.10 (Tokyo International Forum, 4F G409)

Chair: Yuichi Ishikawa (Department of Hematology, Nagoya University Hospital)

Hisayuki Yokoyama1, Nobuyuki Aotsuka2, Kiyoshi Ando3, Hiroatsu Iida4, Takayuki Ishikawa5, Kensuke Usuki6, Masahiro Onozawa7, Masahiro Kizaki8, Kohmei Kubo9, Junya Kuroda10, Yukio Kobayashi11, Takayuki Shimizu12, Shigeru Chiba13, Miho Nara14, Tomoko Hata15, Michihiro Hidaka16, Shinichiro Fujiwara17, Naoko Hosono18, Yoshinobu Maeda19, Yasuyoshi Morita20, Mikiko Kusano21, Qiaoyang Lu22, Shuichi Miyawaki23, Erkut Bahceci22, Tomoki Naoe24 (1.Sendai Medical Center, Sendai, Japan, 2.Japanese Red Cross Narita Hospital, Narita, Japan, 3.Tokai University School of Medicine, Isehara, Japan, 4.NHO Nagoya Medical Center, Nagoya, Japan, 5.Kobe City Medical Center General Hospital, Kobe, Japan, 6.NTT Medical Center Tokyo, Tokyo, Japan, 7.Hokkaido University, Sapporo, Japan, 8.Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 9.Aomori Prefectural Central Hospital, Aomori, Japan, 10.Kyoto Prefectural University of Medicine, Kyoto, Japan, 11.International University of Health and Welfare, Mita Hospital, Tokyo, Japan, 12.Keio University School of Medicine, Tokyo, Japan, 13.University of Tsukuba, Tsukuba, Japan, 14.Akita University, Akita, Japan, 15.Nagasaki University, Nagasaki, Japan, 16.Kumamoto Medical Center, Kumamoto, Japan, 17.Jichi Medical University, Shimotsuke, Japan, 18.University of Fukui, Fukui, Japan, 19.Okayama University Hospital, Okayama, Japan, 20.Kindai University, Osaka, Japan, 21.Astellas Pharma, Inc., Tokyo, Japan, 22.Astellas Pharma US, Inc., Northbrook, IL, USA, 23.Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 24.NHO Nagoya Medical Center, Nagoya, Japan)

Toru Sakura1, Hiroatsu Iida2, Takayuki Ishikawa3, Kensuke Usuki4, Shin Fujisawa5, Toshihiro Miyamoto6, Satoshi Morita7, Bahceci Erkut8, Masahito Kaneko9, Takeshi Kadokura9, Musashi Fukuda9, Shuichi Miyawaki10, Tomoki Naoe2 (1.Saiseikai Maebashi Hospit., Gunma Japan, 2.NHO Nagoya Medical Center, Nagoya, Japan, 3.Kobe City Medical Center General Hospital, 4.NTT Medical Center Tokyo, Tokyo, Japan, 5.Yokohama City University Medical Center, Japan, 6.Kyushu University, Fukuoka, Japan, 7.Kyoto University, Kyoto, Japan, 8.Astellas Pharma, US Inc., Northbrook, IL, USA, 9.Astellas Pharma, Inc., Tokyo, Japan, 10.Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan)

Goichi Yoshimoto1, Erkut Bahceci2, Elizabeth Shima Rich2, Minoru Kameda3, Ruishan Wu2, Shuichi Miyawaki4, Tomoki Naoe5 (1.Hematology, Oncology and Cardiovascular Medicine, Kyushu Univ, Fukuoka, Japan, 2.Astellas Pharma US, Inc, 3.Astellas Pharma, Inc., Tokyo, Japan, 4.Hematol., Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 5.NHO Nagoya Medical Center, Nagoya, Japan)

Ilseung Choi1, Shuichi Ota2, Satoshi Ichikawa3, Naohito Fujishima4, Hiroatsu Iida5, Isamu Sugiura6, Koichi Sugiura7, Masaya Tachibana7, Shoichi Ohwada7, Daisuke Kuroki7, Sakura Sakajiri8 (1.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 2.Sapporo Hokuyu Hospital, Sapporo, Japan, 3.Tohoku University Hospital, Sendai, Japan, 4.Akita University Hospital, Akita, Japan, 5.National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 6.Toyohashi Municipal Hospital, Toyohashi, Japan, 7.Daiichi Sankyo Co., Ltd., Tokyo, Japan, 8.Juntendo University Urayasu Hospital, Urayasu, Japan)

Alexander E. Perl1, Jorge E. Cortes2, Samer K. Khaled3, Giovanni Martinelli4, Siddhartha Ganguly5, Nigel H. Russell6, Alwin Kramer7, Herve Dombret8, Donna Hogge9, Brian A. Jonas10, Anskar Y.-H. Leung11, Priyanka Mehta12, Pau Montesinos13, Markus P. Radsak14, Simona Sica15, Meena Arunachalam16, Melissa Holmes16, Ken Kobayashi16, Ruth Namuyinga16, Nanxiang Ge16, Antoine Yver16, Yufen Zhang16, Mark J. Levis17 (1.Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America, 2.Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 3.Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, United States of America, 4.Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italian Republic, 5.University of Kansas Medical Center, Westwood, KS, United States of America, 6.Nottingham University Hospital, Nottingham, United Kingdom of Great Britain and Northern Ireland, 7.Klinische Kooperationseinheit Molekulare Hamatologie/Onkologie, Medizinische Klinik V, Universitat Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Federal Republic of Germany, 8.University Paris Diderot, Saint-Louis Hospital, Paris, French Republic, 9.Vancouver General Hospital, Vancouver, Canada, 10.University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States of America, 11.The University of Hong Kong, Hong Kong, People's Republic of China, 12.The University of Bristol, Bristol, United Kingdom of Great Britain and Northern Ireland, 13.Hospital Universitari i Politecnic La Fe, Valencia, Spain, 14.Department of Hematology, Medical Oncology, & Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Federal Republic of Germany, 15.Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Italian Republic, 16.Daiichi Sankyo, Inc., Basking Ridge, NJ, United States of America, 17.Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States of America)